论文部分内容阅读
目的探讨蒲地蓝消炎口服液联合头孢噻肟钠治疗急性肠系膜淋巴结炎的临床疗效。方法选取2016年1月—2017年1月在安康市人民医院进行治疗的88例急性肠系膜淋巴结炎患者为研究对象,根据治疗方案的差别分为对照组(44例)和治疗组(44例)。对照组患者静脉滴注注射用头孢噻肟钠,60~100 mg/(kg·d)加入生理盐水100 m L,2次/d。治疗组在对照组基础上口服蒲地蓝消炎口服液,10 m L/次,3次/d。两组患者均治疗7 d。评价两组患者临床疗效,同时比较治疗前后两组患者临床症状消失时间和血清学指标差异。结果治疗后,对照组总有效率为81.82%,显著低于治疗组的97.73%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组患者腹痛、食欲不振、呕吐和腹泻消失时间均显著短于对照组患者,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清C反应蛋白(CRP)和降钙素(PCT)水平均明显降低,同组比较差异具有统计学意义(P<0.05);且治疗组上述指标明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论蒲地蓝消炎口服液联合头孢噻肟钠治疗急性肠系膜淋巴结炎可有效改善患者临床症状,降低机体炎症反应,具有一定的临床推广应用价值。
Objective To investigate the clinical effect of Puda Lan Xiao Yan oral liquid combined with cefotaxime sodium in the treatment of acute mesenteric lymphadenitis. Methods A total of 88 patients with acute mesenteric lymphadenitis treated in Ankang People’s Hospital from January 2016 to January 2017 were selected and divided into control group (44 cases) and treatment group (44 cases) according to the difference of treatment regimen. . Patients in the control group were given intravenous cefotaxime sodium for injection, and saline 100 ml twice daily for 60-100 mg / (kg · d). The treatment group was given poyanglan anti-inflammatory oral solution on the basis of the control group, 10 m L / time, 3 times / d. Both groups were treated for 7 days. The clinical efficacy of the two groups was evaluated, and the differences of clinical symptoms disappear time and serological indexes between the two groups before and after treatment were compared. Results After treatment, the total effective rate of the control group was 81.82%, which was significantly lower than that of the treatment group (97.73%). The difference between the two groups was statistically significant (P <0.05). After treatment, the patients in the treatment group had significantly shorter abdominal pain, loss of appetite, vomiting and disappearance of diarrhea than those in the control group. There was significant difference between the two groups (P <0.05). After treatment, serum C-reactive protein (CRP) and calcitonin (PCT) levels were significantly decreased in both groups, with statistical significance (P <0.05); and the above indicators in the treatment group were significantly lower than those in the control group The difference between the two groups was statistically significant (P <0.05). Conclusion Pudilan anti-inflammatory oral liquid combined with cefotaxime sodium in the treatment of acute mesenteric lymphadenitis can effectively improve the clinical symptoms and reduce the inflammatory reaction in the body, and has certain clinical application value.